Vivo Bio Tech Ltd secures landmark Pre-Clinical Testing Contract Valued at ₹10.75 Crores

Vivo Bio Tech Limited announces a significant milestone in its growth journey. The company has been awarded a pre-clinical testing contract valued at ₹10.75 Crores for a novel molecule, in collaboration with a leading Indian Pharma and Agro-Chemical major.

This contract entrusts Vivo Bio Tech Limited with the end-to-end responsibility of conducting the full spectrum of pre-clinical safety and regulatory studies, including:

- Toxicity studies across multiple endpoints

- Mutagenicity evaluations to assess genetic safety

- Ecotoxicology studies for environmental risk assessment

- Comprehensive analytical services

All studies will be executed under the Section 9(3) requirements with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC)-India's apex body for approvals.

By undertaking this comprehensive mandate, Vivo Bio Tech Limited joins a select group of CROs in India with the infrastructure and scientific expertise to deliver integrated pre-clinical solutions that meet both national and international regulatory standards.

Mr. Chandrasekar Patnaik, Chief Business Officer, Vivo Bio Tech Limited, said: "This milestone reaffirms Vivo Bio Tech's scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services."

This landmark contract further underscores Vivo Bio Tech Limited's growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It reflects the company's long-term vision of evolving from a drug discovery services provider into a strategic coinnovator with large pharma and biotech companies. By enabling safer and more effective products to reach global markets while paving the way for future collaborations in joint drug discovery and milestone-driven partnerships, Vivo Bio Tech Limited is positioning itself as the ultimate benchmark of a next-generation CRO.

Shares of VIVO BIO TECH LTD. was last trading in BSE at Rs. 37.26 as compared to the previous close of Rs. 36.71. The total number of shares traded during the day was 20042 in over 95 trades.

The stock hit an intraday high of Rs. 37.50 and intraday low of 36.11. The net turnover during the day was Rs. 745835.00.

Source : Equity Bulls

Keywords

VIVOBIOTECH INE380K01017 Biotechnology OrderWin PreClinicalTesting